We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
26
DELISTED
ESSA Pharma
EPIX
$67M 1.02%
7,889,583
-9,000
-0.1% -$78.6K
IMCR icon
27
Immunocore
IMCR
$1.78B
$63.2M 0.96%
972,254
-3,800
-0.4% -$261K
BHVN icon
28
Biohaven
BHVN
$2.32B
$62.9M 0.96%
1,150,000
+75,000
+7% +$3.71M
OPCH icon
29
Option Care Health
OPCH
$3.41B
$62.6M 0.96%
1,867,263
-71,544
-4% -$2.32M
CRL icon
30
Charles River Laboratories
CRL
$10.8B
$62.2M 0.95%
229,697
+11,941
+5% +$2.85M
INSM icon
31
Insmed
INSM
$23.5B
$58.1M 0.89%
2,141,843
-149,115
-7% -$4.17M
AXSM icon
32
Axsome Therapeutics
AXSM
$11.8B
$54.7M 0.83%
685,476
+50,104
+8% +$4.21M
BIO icon
33
Bio-Rad Laboratories Class A
BIO
$8.15B
$54.2M 0.83%
156,618
+15,471
+11% +$5.09M
HCA icon
34
HCA Healthcare
HCA
$82.3B
$53.3M 0.81%
159,703
+7,525
+5% +$2.3M
ELV icon
35
Elevance Health
ELV
$80.9B
$51.1M 0.78%
98,612
-9,176
-9% -$4.56M
ALGN icon
36
Align Technology
ALGN
$12.7B
$50.8M 0.77%
154,909
-4,498
-3% -$1.32M
IDXX icon
37
Idexx Laboratories
IDXX
$44.8B
$50.4M 0.77%
93,358
-752
-0.8% -$411K
PODD icon
38
Insulet
PODD
$11.4B
$50.4M 0.77%
293,828
+3,928
+1% +$733K
ACCD
39
DELISTED
Accolade Inc
ACCD
$50.4M 0.77%
4,804,514
+297,110
+7% +$3.38M
RLAY icon
40
Relay Therapeutics
RLAY
$4.34B
$49.2M 0.75%
5,926,618
-9,464
-0.2% -$92.3K
EVH icon
41
Evolent Health
EVH
$654M
$48.6M 0.74%
1,483,096
-893,896
-38% -$28.5M
HUM icon
42
Humana
HUM
$48B
$47M 0.72%
135,541
+35,069
+35% +$13.3M
INSP icon
43
Inspire Medical Systems
INSP
$1.46B
$46.8M 0.71%
217,694
+2,094
+1% +$410K
GEHC icon
44
GE HealthCare
GEHC
$28.7B
$46.6M 0.71%
512,230
-22,954
-4% -$1.91M
EXEL icon
45
Exelixis
EXEL
$14.1B
$45.2M 0.69%
1,903,200
-204,900
-10% -$4.55M
LLY icon
46
Eli Lilly
LLY
$1.05T
$45.1M 0.69%
57,965
+1,753
+3% +$1.25M
PRCT icon
47
Procept Biorobotics
PRCT
$1.09B
$44M 0.67%
890,114
+4,768
+0.5% +$227K
BDTX icon
48
Black Diamond Therapeutics
BDTX
$103M
$43.2M 0.66%
8,517,839
-18,000
-0.2% -$72.6K
CRSP icon
49
CRISPR Therapeutics
CRSP
$4.71B
$42.3M 0.64%
619,950
-280,450
-31% -$20.1M
CDNA icon
50
CareDx
CDNA
$2.05B
$41.7M 0.64%
3,934,006
-20,786
-0.5% -$208K
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.